{"disease":{"id":"metastatic-breast-cancer-first-line","name":"metastatic breast cancer first line"},"drugs":{"marketed":[{"drug_id":"trastuzumab-anns","indication_name":"Metastatic Breast Cancer - First Line","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"KANJINTI","generic_name":"TRASTUZUMAB-ANNS","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06278870","title":"Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":312,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}